olaparib + enzalutamide + abiraterone acetate + Prednisone
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Metastatic Castration-resistant Prostate Cancer
Conditions
Metastatic Castration-resistant Prostate Cancer
Trial Timeline
Jul 29, 2022 → Jul 30, 2025
NCT ID
NCT05457257About olaparib + enzalutamide + abiraterone acetate + Prednisone
olaparib + enzalutamide + abiraterone acetate + Prednisone is a approved stage product being developed by AstraZeneca for Metastatic Castration-resistant Prostate Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT05457257. Target conditions include Metastatic Castration-resistant Prostate Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Castration-resistant Prostate Cancer were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05457257 | Approved | Completed |
Competing Products
20 competing products in Metastatic Castration-resistant Prostate Cancer